Does preoperative locally applied estrogen treatment facilitate prolapse‐associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double‐masked, placebo‐controlled, multicentre study
| Autor: | Marie-Louise Marschalek, Heinrich Husslein, Wolf Dietrich, Christian Obruca, Heinz Koelbl, Wolfgang Umek, Sonja Zehetmayer, Raffaela Morgenbesser, Oliver Kimberger, Klaus Bodner, Barbara Bodner-Adler |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Multivariate analysis medicine.drug_class Population Placebo Pelvic Organ Prolapse Vaginal estrogen Double-Blind Method Internal medicine Humans Medicine Prospective Studies education Aged education.field_of_study Estrogens Conjugated (USP) Intraoperative Care Pelvic floor Estradiol business.industry Confounding Obstetrics and Gynecology Estrogens Pelvic Floor Middle Aged Postmenopause Administration Intravaginal Treatment Outcome medicine.anatomical_structure Estrogen Female business Sexual function |
| Zdroj: | BJOG: An International Journal of Obstetrics & Gynaecology. 128:2200-2208 |
| ISSN: | 1471-0528 1470-0328 |
| DOI: | 10.1111/1471-0528.16894 |
| Popis: | OBJECTIVE To evaluate whether locally applied vaginal estrogen affects prolapse-associated complaints compared with placebo treatment in postmenopausal women prior to surgical prolapse repair. DESIGN Randomised, double-masked, placebo-controlled, multicentre study. SETTING Urogynaecology unit at the Medical University of Vienna and University Hospital of Tulln. POPULATION Postmenopausal women with symptomatic pelvic organ prolapse and planned surgical prolapse repair. METHODS Women were randomly assigned local estrogen cream or placebo cream 6 weeks preoperatively. MAIN OUTCOME MEASURES The primary outcome was differences in subjective prolapse-associated complaints after 6 weeks of treatment prior to surgery, assessed with the comprehensive German pelvic floor questionnaire. Secondary outcomes included differences in other pelvic floor-associated complaints (bladder, bowel or sexual function). RESULTS Out of 120 women randomised, 103 (86%) remained for the final analysis. After 6 weeks of treatment the prolapse domain score did not differ between the estrogen and the placebo groups (4.4 ± 0.19 versus 4.6 ± 0.19; mean difference, -0.21; 95% CI -0.74 to 0.33; P = 0.445). Multivariate analysis, including only women receiving the intervention, showed that none of the confounding factors modified the response to estradiol. CONCLUSIONS These results demonstrate that preoperative locally applied estrogen does not ameliorate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse. TWEETABLE ABSTRACT Preoperative local estrogen does not ameliorate prolapse-associated symptoms in postmenopausal women with pelvic organ prolapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text